Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
The National Institute for Health and Care Excellence has issued guidelines recommending the drug as an option for treating progressive MTC in adults with unresectable, locally advanced or metastatic disease.
Read more: http://www.pharmatimes.com/news/final_nice_green_light_for_ipsens_cometriq_1229604